Warning: The NCBI web site requires JavaScript to function. more...
Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis.
van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW.
Arthritis Res Ther. 2005;7(5):R949-58. Epub 2005 Jun 14.
Related citations
Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, Rönnelid J.
Arthritis Rheum. 2008 Jan;58(1):36-45.
Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset.
Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, Rantapää-Dahlqvist S.
Ann Rheum Dis. 2006 Apr;65(4):453-8. Epub 2005 Sep 21.
Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.
van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW.
Arthritis Rheum. 2004 Mar;50(3):709-15.
Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, van der Helm-van Mil AH.
Arthritis Rheum. 2009 Aug;60(8):2232-41.
Is Anti Cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis?
Girelli F, Foschi FG, Bedeschi E, Calderoni V, Stefanini GF, Martinelli MG.
Eur Ann Allergy Clin Immunol. 2004 Apr;36(4):127-30.
Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage.
Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B.
Ann Rheum Dis. 2003 Feb;62(2):120-6.
[Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis].
Us D, Gülmez D, Hasçelik G.
Mikrobiyol Bul. 2003 Apr-Jun;37(2-3):163-70. Turkish.
Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis.
van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, van Venrooij WJ, Verweij CL, Toes RE, de Vries RR.
Arthritis Rheum. 2004 Jul;50(7):2113-21.
Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis.
Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ, Carrier N, Daniel C, Ménard HA.
Arthritis Res Ther. 2005;7(3):R592-603. Epub 2005 Mar 17.
Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis.
Inanc N, Dalkilic E, Kamali S, Kasapoglu-Günal E, Elbir Y, Direskeneli H, Inanc M.
Clin Rheumatol. 2007 Jan;26(1):17-23. Epub 2006 Mar 15.
Anti-cyclic citrullinated peptide antibodies--activity markers in rheumatoid arthritis.
Predeteanu D, Varzaru L, Balanescu A, Bojinca V, Opris D, Vlad V, Berghea F, Abobului M, Constantinescu C, Ionescu R.
J Med Life. 2009 Jan-Mar;2(1):36-41.
Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project.
Svärd A, Kastbom A, Reckner-Olsson A, Skogh T.
Arthritis Res Ther. 2008;10(4):R75. Epub 2008 Jul 4.
Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study.
Syversen SW, Goll GL, van der Heijde D, Landewé R, Lie BA, Odegård S, Uhlig T, Gaarder PI, Kvien TK.
Ann Rheum Dis. 2010 Feb;69(2):345-51. Epub 2009 Jul 30.
Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
Lim MK, Sheen DH, Lee YJ, Mun YR, Park M, Shim SC.
J Rheumatol. 2009 Apr;36(4):712-6. Epub 2009 Mar 13.
Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression.
Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF.
Ann Rheum Dis. 2005 Dec;64(12):1744-9. Epub 2005 Apr 20.
Antibodies to citrullinated peptides are not associated with the rate of joint destruction in patients with a well-established diagnosis of rheumatoid arthritis.
Nieto-Colonia AM, Santos WS, Keusseyan SP, Caldana W, Fernandes AR, Andrade LE.
Braz J Med Biol Res. 2008 Mar;41(3):188-92. Epub 2008 Jan 11.
Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR.
J Rheumatol. 2008 Jun;35(6):1002-8. Epub 2008 Apr 1.
The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.
van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR.
Arthritis Rheum. 2006 Apr;54(4):1117-21.
Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness.
del Val del Amo N, Ibanez Bosch R, Fito Manteca C, Gutierrez Polo R, Loza Cortina E.
Clin Exp Rheumatol. 2006 May-Jun;24(3):281-6.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on